Silica nanoparticles without any surface modification are not surface active at the toluene−water interface due to their extreme hydrophilicity but can be surface activated in situ by adsorbing ...cationic surfactant from water. This work investigates the effects of the molecular structure of water-soluble cationic surfactant on the surface activation of the nanoparticles by emulsion characterization, adsorption and zeta potential measurements, dispersion stability experiments, and determination of relevant contact angles. The results show that an adsorbed cationic surfactant monolayer on particle surfaces is responsible for the wettability modification of the particles. In the presence of a trace amount of cationic surfactant, the hydrophobicity of the particles increases, leading to the formation of stable oil-in-water O/W(1) emulsions. At high surfactant concentration (>cmc) the particle surface is retransformed to hydrophilic due to double-layer or hemimicelle formation, and the concentration of the free surfactant in the aqueous phase is high enough to stabilize emulsions alone. O/W(2) emulsions, probably costabilized by free surfactant and particles, are then formed. The monolayer adsorption seems to be charge-site dependent. Thus, using single-chain trimethylammonium bromide surfactants or a double-head gemini cationic surfactant, the hydrophobicity of the particles achieved is not sufficient to stabilize water-in-oil (W/O) emulsions, and no phase inversion is induced. However, using a double-chain cationic surfactant, the chain density on the particle surfaces endows them with a hydrophobicity high enough to stabilize W/O emulsions, and double phase inversion, O/W(1) → W/O → O/W(2), can then be achieved by increasing the surfactant concentration.
The in situ surface activation of unmodified CaCO3 nanoparticles by interaction with surfactant in aqueous media has been studied, and the impact of this on the foamability and foam stability of ...aqueous dispersions was assessed. Using complementary experiments including measurement of particle zeta potentials, adsorption isotherms of surfactant, air−water surface tensions, and relevant contact angles, the mechanism of this activation was revealed. The results show that the non-surface-active CaCO3 nanoparticles cannot be surface activated by interaction with cationic or nonionic surfactants but can be surface activated by interaction with anionic surfactants such as SDS and AOT, leading to a synergistic effect in both foamability and foam stability. The electrostatic interaction between the positive charges on particle surfaces and the negative charges of anionic surfactant headgroups results in monolayer adsorption of the surfactant at the particle−water interface and transforms the particles from hydrophilic to partially hydrophobic such that particles become surface active and stabilize bubbles. SDS is a more efficient surfactant for this surface activation than AOT. Possible reasons for this difference are suggested.
This systematic review and meta-analysis estimated the global, regional prevalence, and risk factors of osteoporosis. Prevalence varied greatly according to countries (from 4.1% in Netherlands to ...52.0% in Turkey) and continents (from 8.0% in Oceania to 26.9% in Africa). Osteoporosis is a common metabolic bone disorder in the elderly, usually resulting in bone pain and an increased risk of fragility fracture, but few summarized studies have guided global strategies for the disease. Therefore, we pooled the epidemiologic data to estimate the global, regional prevalence, and potential risk factors of osteoporosis. We conducted a comprehensive literature search through PubMed, EMBASE, Web of Science, and Scopus, to identify population-based studies that reported the prevalence of osteoporosis based on the World Health Organization (WHO) criteria. Meta-regression and subgroup analyses were used to explore the sources of heterogeneity. The study was registered in the PROSPERO database (CRD42021285555). Of the 57,933 citations evaluated, 108 individual studies containing 343,704 subjects were included. The global prevalence of osteoporosis and osteopenia was 19.7% (95%CI, 18.0%–21.4%) and 40.4% (95%CI, 36.9%–43.8%). Prevalence varied greatly according to countries (from 4.1% in Netherlands to 52.0% in Turkey) and continents (from Oceania 8.0% to 26.9% in Africa). The prevalence was higher in developing countries (22.1%, 95%CI, 20.1%–24.1%) than in developed countries (14.5%, 95%CI, 11.5%–17.7%). Our study indicates a considerable prevalence of osteoporosis among the general population based on WHO criteria, and the prevalence varies substantially between countries and regions. Future studies with robust evidence are required to explore risk factors to provide effective preventive strategies for the disease.
Films of iron selenide (FeSe) one unit cell thick grown on strontium titanate (SrTiO3 or STO) substrates have recently shown superconducting energy gaps opening at temperatures close to the boiling ...point of liquid nitrogen (77 K), which is a record for the iron-based superconductors. The gap opening temperature usually sets the superconducting transition temperature Tc, as the gap signals the formation of Cooper pairs, the bound electron states responsible for superconductivity. To understand why Cooper pairs form at such high temperatures, we examine the role of the SrTiO3 substrate. Here we report high-resolution angle-resolved photoemission spectroscopy results that reveal an unexpected characteristic of the single-unit-cell FeSe/SrTiO3 system: shake-off bands suggesting the presence of bosonic modes, most probably oxygen optical phonons in SrTiO3, which couple to the FeSe electrons with only a small momentum transfer. Such interfacial coupling assists superconductivity in most channels, including those mediated by spin fluctuations. Our calculations suggest that this coupling is responsible for raising the superconducting gap opening temperature in single-unit-cell FeSe/SrTiO3.
Rotating radio transients (RRATs), loosely defined as objects that are discovered through only their single pulses, are sporadic pulsars that have a wide range of emission properties. For many of ...them, we must measure their periods and determine timing solutions relying on the timing of their individual pulses, while some of the less sporadic RRATs can be timed by using folding techniques as we do for other pulsars. Here, based on Parkes and Green Bank Telescope (GBT) observations, we introduce our results on eight RRATs including their timing-derived rotation parameters, positions, and dispersion measures (DMs), along with a comparison of the spin-down properties of RRATs and normal pulsars. Using data for 24 RRATs, we find that their period derivatives are generally larger than those of normal pulsars, independent of any intrinsic correlation with period, indicating that RRATs' highly sporadic emission may be associated with intrinsically larger magnetic fields. We carry out Lomb-Scargle tests to search for periodicities in RRATs' pulse detection times with long timescales. Periodicities are detected for all targets, with significant candidates of roughly 3.4 hr for PSR J1623−0841 and 0.7 hr for PSR J1839−0141. We also analyze their single-pulse amplitude distributions, finding that log-normal distributions provide the best fits, as is the case for most pulsars. However, several RRATs exhibit power-law tails, as seen for pulsars emitting giant pulses. This, along with consideration of the selection effects against the detection of weak pulses, imply that RRAT pulses generally represent the tail of a normal intensity distribution.
This randomized, double‐blind, placebo‐controlled study evaluated whether lamivudine given during late pregnancy can reduce hepatitis B virus (HBV) perinatal transmission in highly viraemic mothers. ...Mothers were randomized to either lamivudine 100 mg or placebo from week 32 of gestation to week 4 postpartum. At birth, infants received recombinant HBV vaccine with or without HBIg and were followed until week 52. One hundred and fifty mothers, with a gestational age of 26–30 weeks and serum HBV DNA >1000 MEq/mL (bDNA assay), were treated. A total of 141 infants received immunoprophylaxis at birth. In lamivudine‐treated mothers, 56 infants received vaccine + HBIg (lamivudine + vaccine + HBIg) and 26 infants received vaccine (lamivudine + vaccine). In placebo‐treated mothers, 59 infants received vaccine + HBIg (placebo + vaccine + HBIg). At week 52, in the primary analyses where missing data was counted as failures, infants in the lamivudine + vaccine + HBIg group had a significant decrease in incidence of HBsAg seropositivity (10/56, 18%vs 23/59, 39%; P = 0.014) and in detectable HBV DNA (11/56, 20%vs 27/59, 46%; P = 0.003) compared to infants in the placebo + vaccine + HBIg group. Sensitivity analyses to evaluate the impact of missing data at week 52 resulting from a high dropout rate (13% in the lamivudine + vaccine + HBIg group and 31% in the placebo + vaccine + HBIg group) remained consistent with the primary analysis in that lower transmission rates were still observed in the infants of lamivudine‐treated mothers, but the differences were not statistically significant. No safety concerns were noted in the lamivudine‐treated mothers or their infants. Results of this study suggest that lamivudine reduced HBV transmission from highly viraemic mothers to their infants who received passive/active immunization.
Patients with a germline
or
mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor ...activity in this population.
We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients who had a germline
or
mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review.
Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval CI, 0.35 to 0.82; P = 0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs. 18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event.
Among patients with a germline
mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).
PDF
